Tsai, Mao-SongMao-SongTsaiHSIN-YUN SUNChen, Cheng-PinCheng-PinChenLee, Chen-HsiangChen-HsiangLeeLee, Chun-YuanChun-YuanLeeLiu, Chun-EngChun-EngLiuTang, Hung-JenHung-JenTangHung, Tung-CheTung-CheHungLi, Chia-WenChia-WenLiLee, Yuan-TiYuan-TiLeeLiou, Bo-HuangBo-HuangLiouYang, Chia-JuiChia-JuiYangCHIEN-CHING HUNG2023-02-142023-02-142023-0112019712https://scholars.lib.ntu.edu.tw/handle/123456789/628012Real-world experience with coformulated bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF) is sparse as a switch regimen among people living with HIV (PLWH) having achieved viral suppression after previous virologic failures with the emergence of K65N/R.enGenetic barrier; Integrase strand-transfer inhibitor; Low-level viremia; Nucleoside reverse-transcriptase inhibitor; Resistance-associated mutation; Viral rebound[SDGs]SDG3journal article10.1016/j.ijid.2022.11.012363841862-s2.0-85144636045https://api.elsevier.com/content/abstract/scopus_id/85144636045